The maintenance of a Neutral rating and a $3.5 price target by Mizuho suggests no significant short-term price movement is expected for Corvus Pharma. The analyst's view likely reflects a balanced outlook on the company's prospects, without strong indicators for either positive or negative performance in the near term.